On October 10, 2025, Legend Biotech announced that the U.S. FDA approved a label update for CARVYKTI® to include overall survival data showing a statistically significant improvement for patients with multiple myeloma. The update also warns of serious side effects such as immune effector cell-associated enterocolitis and complications from JC virus reactivation.